



January 22, 2026

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai-400001

**Code: 532321**

**National Stock Exchange of India Limited**

Exchange Plaza,  
C/1, Block G,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Code: Zyduslife**

**Re.: Press Release**

Dear Sir / Madam,

Please find enclosed a copy of press release dated January 22, 2026, titled "**Zydus launches the world's first biosimilar of Nivolumab, 'Tishtha™', in India to treat multiple cancers**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Yours faithfully,  
For, **ZYDUS LIFESCIENCES LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY AND COMPLIANCE OFFICER**  
**MEMBERSHIP NO. FCS7063**

**Encl.: As above**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878



**Zydus launches the world's first biosimilar of Nivolumab, 'Tishtha™', in India to treat multiple cancers**

- *The immunotherapy reduces treatment burden by making it accessible at approximately 1/4th cost of the reference drug*
- *The treatment is likely to benefit more than 5 lakh patients*

*Ahmedabad, 22 January, 2026*

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus"), an innovation-led life-sciences company with an international presence has launched the world's first biosimilar of Nivolumab in India under the brand name Tishtha™, reinforcing the company's growing capability in advanced biologics and Immuno-Oncology. Tishtha™ will be available in 100 mg and 40 mg dosages priced at ₹28,950 and ₹13,950 respectively. The prices are approximately 1/4<sup>th</sup> of the reference drug. This will improve affordability and reduce the overall treatment burden for patients. The two-strength portfolio enables oncologists to optimise dosing and minimise wastage – a key driver of treatment economics in immunotherapy.

Speaking on the development, Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Ltd., said, "At Zydus, we believe every patient deserves timely access to affordable, advanced cancer care. With the launch of Tishtha™, we are expanding access to Immuno-Oncology through a patient-centric therapy. Our aim is to support patients with consistent care throughout their treatment journey. We remain committed to improving patient access to high-quality biosimilar immunotherapies."

Access to modern treatment is determined by three critical factors: consistency, affordability, and reach. Reliable availability of checkpoint inhibitors \*\* is essential for cancer patients who require therapy over multiple cycles, as interruptions may add both clinical and financial stress for families. Developed and manufactured in India, Tishtha™ ensures long-term dependability for patients throughout their treatment journey. For patients living with cancer, sustained and predictable access to therapy is critical. By introducing Tishtha™ in India, Zydus expands access to advanced Immuno-Oncology treatment.

**About Zydus Lifesciences Limited**

Zydus Lifesciences Limited is an innovation-led life-sciences company with leadership positions across pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise and a global footprint across the United States, India and other international markets. As of September 30, 2025, the group employs 29,000 people worldwide including 1,500 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit [www.zyduslife.com](http://www.zyduslife.com)



For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878

**PRESS  
RELEASE**



*\*\*The immune system uses checkpoint proteins on immune cells to tell the difference between normal cells and those it sees as foreign, such as germs and cancer cells. These checkpoints act like switches that turn immune responses on or off, helping the body avoid attacking its own tissues. Some cancer cells find ways to use these checkpoints to avoid being recognized and destroyed. Immune checkpoint inhibitors block the signals from these checkpoints, allowing the immune system to find and attack the cancer cells.*

<https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html>



For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878